Using the new HPV vaccines in clinical practice

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 10, 2006, Pages 929-935

  Widdice, Lea E ^a   Kahn, Jessica A ^a,b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b National Network for Immunization Information   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONDYLOMA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE PAIN; PAPANICOLAOU TEST; SCHOOL CHILD; SEXUAL BEHAVIOR; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 33750070612     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.10.929     Document Type: Article

References (44)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
2. Shin HR, Franceschl S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004; 190:468-476.
3. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-226.
4. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006, 24(suppl 1):S1-S15.
5. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-163.
6. Centers for Disease Control and Prevention. Genital HPV Infection - CDC Fact Sheet. Centers for Disease Control and Prevention; 2004.
7. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37(suppl 6):S3-S9.
8. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997-1003.
9. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. Br J Obstet Gynaecol 2002; 109:96-98.
10. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645-2654.
11. Vaccarella S, Franceschi S, Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006, 15:326-333.
12. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002; 89:183-190.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
14. Tjiong MY, Out TA, Ter Schegget J, Burger MP, Van Der Vange N. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review. Int J Gynecol Cancer 2001; 11:9-17.
15. CancerMondial. International Agency for Research on Cancer. www-dep.iarc.fr/. Accessed August 23, 2006.
16. Centers for Disease Control and Prevention. Cancer Registries and Surveillance. www.cdc.gov/cancer/npcr/uscs/index.htm. Accessed August 24, 2006.
17. National Cancer Institute. Surveillance Epidemiology and End Results. http://seer.cancer.gov/. Accessed August 24, 2006.
18. Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458-467.
19. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101:270-280.
20. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363:1488-1489.
21. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316-3322.
22. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993; 20:10-13.
23. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004, 70:2335-2342.
24. Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 2005; 13:354-359.
25. Centers for Disease Control and Prevention. ACIP Provisional Recommendations for the Use of Quadrivalent HPV Vaccine. www.cdc.gov/ nip/. Accessed August 24, 2006.
26. Villa LL, Costa RL, Pette CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
27. Skjeldestad FE, FUTURE II Steering Committee. prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervial intraepithelial neoplasia (CIN) 2/3 risk [abstract]. Presented at the 43rd annual meeting of the Infectious Disease Society of North America, San Francisco, CA, October 5-9, 2005.
28. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.
29. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
30. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106:896-904.
31. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284-292.
32. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13:631-639.
33. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 2005; 37:502-510.
34. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol 2005; 18:391-398.
35. Raley JC, Followwill KA, Zimet GD, Ault KA. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol 2004; 12:127-133.
36. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000; 9:47-50.
37. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003; 14:300-306.
38. Hoover DR, Carfioli B, Moench EA. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 2000; 21:375-391.
39. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006; 117:1486-1493.
40. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005; 37:248-251.
41. Zimet GD, Mays RM, Sturm LA. Revert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med 2005; 159:132-137.
42. Gilbert LK, Alexander L, Grosshans JF, Jolley L. Answering frequently asked questions about HPV. Sex Transm Dis 2003; 30:193-194.
43. Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin 2004; 54:248-259.
44. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004; 8:188-194.